| MeSH term | MeSH ID | Detail |
|---|---|---|
| Pain | D010146 | 64 associated lipids |
| Dermatitis, Contact | D003877 | 59 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Weight Loss | D015431 | 56 associated lipids |
| Parkinson Disease | D010300 | 53 associated lipids |
| Nerve Degeneration | D009410 | 53 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Kidney Failure, Chronic | D007676 | 51 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hirano Y et al. | Morphological and functional changes of islets of Langerhans in FK506-treated rats. | 1992 | Transplantation | pmid:1373536 |
| Takahara S et al. | The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. | 1992 | Transplantation | pmid:1373537 |
| Johnson MC et al. | QT prolongation and Torsades de Pointes after administration of FK506. | 1992 | Transplantation | pmid:1373538 |
| Connelly PR and Thomson JA | Heat capacity changes and hydrophobic interactions in the binding of FK506 and rapamycin to the FK506 binding protein. | 1992 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1375751 |
| Lancaster JR et al. | EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. | 1992 | J. Biol. Chem. | pmid:1375934 |
| Hirai T et al. | The immunosuppressive effect of FK 506 on canine lung transplantation. | 1992 | J. Thorac. Cardiovasc. Surg. | pmid:1375967 |
| Tai PK et al. | Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. | 1992 | Science | pmid:1376003 |
| Lhoëst G et al. | Isolation and mass spectrometric identification of two metabolites of FK 506 from rat liver microsomal incubation media. | 1992 | Pharm Acta Helv | pmid:1279730 |
| Benigni A et al. | The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. | 1992 | Transplantation | pmid:1279848 |
| Mor E et al. | Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. | 1992 | Transplantation | pmid:1279849 |
| Olejniczak ET et al. | A 4D HCCH-TOCSY experiment for assigning the side chain 1H and 13C resonances of proteins. | 1992 | J. Biomol. NMR | pmid:1283353 |
| Bauer S et al. | The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. | 1992 | Int J Clin Pharmacol Ther Toxicol | pmid:1283385 |
| Renoir JM et al. | [Effect of immunosuppressants FK506 and rapamycin on the function of progesterone receptor: protein "p59-HBI", intersection between immunology and endocrinology?]. | 1992 | C. R. Acad. Sci. III, Sci. Vie | pmid:1284044 |
| Natazuka T | FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line. | 1992 | Kobe J Med Sci | pmid:1284834 |
| Sato Y et al. | FK 506 suppresses class II antigen expression in regenerating livers following partial hepatectomy in the rat. | 1992 | Transplant. Proc. | pmid:1379761 |
| Stütz A | Immunosuppressive macrolides. | 1992 | Transplant. Proc. | pmid:1379762 |
| Leiva MC and Lyttle CR | Leukocyte chemotactic activity of FKBP and inhibition by FK506. | 1992 | Biochem. Biophys. Res. Commun. | pmid:1379802 |
| Iwasaki K et al. | Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. | 1992 | Arzneimittelforschung | pmid:1379812 |
| Edalji R et al. | High-level expression of recombinant human FK-binding protein from a fusion precursor. | 1992 | J. Protein Chem. | pmid:1382438 |
| Thomson AW and Starzl TE | FK 506 and autoimmune disease: perspective and prospects. | 1992 | Autoimmunity | pmid:1382646 |
| Christians U et al. | Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. | 1992 | Clin. Chem. | pmid:1382896 |
| Strom TB | Molecular immunology and immunopharmacology of allograft rejection. | 1992 | Kidney Int. Suppl. | pmid:1383599 |
| Wang SC et al. | FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. | 1992 | J. Surg. Res. | pmid:1383612 |
| Jordan ML et al. | Initial studies with FK506 in renal transplantation. | 1991 Sep-Oct | Cleve Clin J Med | pmid:1718631 |
| Goto T et al. | FK 506: historical perspectives. | 1991 | Transplant. Proc. | pmid:1721254 |
| Ochiai T et al. | Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. | 1991 | Transplant. Proc. | pmid:1721255 |
| Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
| Francavilla A et al. | The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. | 1991 | Transplant. Proc. | pmid:1721287 |
| Yagihashi A et al. | The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721318 |
| Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
| Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
| Schreiber SL | Chemistry and biology of the immunophilins and their immunosuppressive ligands. | 1991 | Science | pmid:1702904 |
| Alessiani M et al. | CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721351 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
| Moutabarrik A et al. | In vitro FK 506 kidney tubular cell toxicity. | 1991 | Transplant. Proc. | pmid:1721383 |
| Ohtsuka S et al. | The effect of short-term FK 506 therapy on pancreas transplantation in rats. | 1991 | Transplant. Proc. | pmid:1721413 |
| Yamashita T et al. | Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. | 1991 | Transplant. Proc. | pmid:1721414 |
| Fukuzaki T et al. | Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. | 1991 | Transplant. Proc. | pmid:1721415 |
| Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
| de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
| Lin CY et al. | Effects of FK 506 on the biochemical markers in canine lung allograft rejection. | 1991 | Transplant. Proc. | pmid:1721445 |
| Propper DJ et al. | Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. | 1991 | Transplant. Proc. | pmid:1721446 |
| Hultsch T et al. | Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1712484 |
| Miyahara H et al. | Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. | 1991 | Clin. Immunol. Immunopathol. | pmid:1712688 |
| Nielsen JB et al. | Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. | 1991 | Biochemistry | pmid:2043618 |
| Petros AM et al. | NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. | 1991 | J. Med. Chem. | pmid:1716684 |
| FK 506--an investigational immunosuppressant. | 1991 | Med Lett Drugs Ther | pmid:1716722 | |
| McWhinnie DL and Morris PJ | Combination drug therapies for immunosuppression in transplantation. | 1991 | Ann. Acad. Med. Singap. | pmid:1724724 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |